Showing results (1351-1360 of 1,532) with videos related to

Sort By:
Pageof 154
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Biological background of the genomic variations of cf-DNA in healthy individualsJ Liu, X Chen, J Wang, et al.
Science Translational Medicine|July 26, 2019
AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challengesMatthew R Gardner, Christoph H Fellinger, Lisa M Kattenhorn, et al.
Alcoholism, Clinical and Experimental Research|November 24, 2007
Molecular and cellular events in alcohol-induced muscle diseaseJoaquim Fernandez-Solà, Victor R Preedy, Charles H Lang, et al.
Physical Review Letters|June 9, 2023
Evidence for Band Renormalizations in Strong-Coupling Superconducting Alkali-Fulleride FilmsJ S Zhou, R Z Xu, X Q Yu, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2002
Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coliR A Welch, V Burland, G Plunkett, et al.
Leukemia|April 24, 2023
Targeting DNA polymerase β elicits synthetic lethality with mismatch repair deficiency in acute lymphoblastic leukemiaJi-Yuan Teng, Ding-Peng Yang, Chao Tang, et al.
Physical Review Letters|November 9, 2016
Slater Insulator in Iridate Perovskites with Strong Spin-Orbit CouplingQ Cui, J-G Cheng, W Fan, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 24, 2024
Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerabilityHui Li, Yao Chen, Ming Ding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesC Y Cheah, D Chihara, S Horowitz, et al.
Pageof 154